KOSDAQ large cap
Mezzion Pharma
A pharma company developing rare-disease drugs, pursuing commercialization of udenafil for single-ventricle heart patients. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
140410.KQ Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'21+36.7%'22-79.3%'23+169.1%'24-7.5%'25+445.6%YTD-67.2%
Money in ▸·
Mezzion Pharma
▸ Money out·
Financials & Segments
- Segments · Drug development (udenafil)
Revenue from
No refined links yet.
Pays to
No refined links yet.